Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs
Open Access
- 16 May 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 3 (6), e177
- https://doi.org/10.1371/journal.pmed.0030177
Abstract
Ebola virus causes a hemorrhagic fever syndrome that is associated with high mortality in humans. In the absence of effective therapies for Ebola virus infection, the development of a vaccine becomes an important strategy to contain outbreaks. Immunization with DNA and/or replication-defective adenoviral vectors (rAd) encoding the Ebola glycoprotein (GP) and nucleoprotein (NP) has been previously shown to confer specific protective immunity in nonhuman primates. GP can exert cytopathic effects on transfected cells in vitro, and multiple GP forms have been identified in nature, raising the question of which would be optimal for a human vaccine. To address this question, we have explored the efficacy of mutant GPs from multiple Ebola virus strains with reduced in vitro cytopathicity and analyzed their protective effects in the primate challenge model, with or without NP. Deletion of the GP transmembrane domain eliminated in vitro cytopathicity but reduced its protective efficacy by at least one order of magnitude. In contrast, a point mutation was identified that abolished this cytopathicity but retained immunogenicity and conferred immune protection in the absence of NP. The minimal effective rAd dose was established at 1010 particles, two logs lower than that used previously. Expression of specific GPs alone vectored by rAd are sufficient to confer protection against lethal challenge in a relevant nonhuman primate model. Elimination of NP from the vaccine and dose reductions to 1010 rAd particles do not diminish protection and simplify the vaccine, providing the basis for selection of a human vaccine candidate.Keywords
This publication has 24 references indexed in Scilit:
- Immunogenicity of Recombinant Fiber-Chimeric Adenovirus Serotype 35 Vector-Based Vaccines in Mice and Rhesus MonkeysJournal of Virology, 2005
- Comprehensive Analysis of Ebola Virus GP1 in Viral EntryJournal of Virology, 2005
- Ebola Virus Glycoprotein Toxicity Is Mediated by a Dynamin-Dependent Protein-Trafficking PathwayJournal of Virology, 2005
- pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGNJournal of Virology, 2004
- Pathogenesis of Ebola Hemorrhagic Fever in Cynomolgus MacaquesThe American Journal of Pathology, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003
- Improved Adenovirus Vectors for Infection of Cardiovascular TissuesJournal of Virology, 2001
- Protection from Ebola Virus Mediated by Cytotoxic T Lymphocytes Specific for the Viral NucleoproteinJournal of Virology, 2001
- An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal MuscleHuman Gene Therapy, 1996
- Characterization of 911: A New Helper Cell Line for the Titration and Propagation of Early Region 1-Deleted Adenoviral VectorsHuman Gene Therapy, 1996